Drug shortages are the results of manufacturing, demand increase and other problems.
advertisementThe European Union lacks 16 medicines that are considered “important” for people’s health.
Put the drug EU shortage list If production problems, demands increase rapidly or pharmacies are decided to be pulled out of the market, everything that restricts the supply of blocks temporarily or permanently.
According to the EMA (European Medicines Agency), 34 medicines are continuously lacking. 16 of them are in the European Commission’s list of essential drugs for the EU. New Criticism.
According to the latest information of the EMA and member states, important medicines that lack the supply of the EU are as follows.
Xi’an cargo addiction
Cyanokit is the only EU approval drug that treats cyan cargo addiction. This includes the active ingredient hydroxicobalamine or vitamin B12A in the list of important medicines of the EU.
In December 2024, the health authorities said that the manufacturing of cyanokit is being suspended after the drug producer found that some of the deployment may have been contaminated. However, according to the EMA, it is still circulating because there is a low risk of contamination and no alternative detox. The tribe is expected to be resolved by May 2025.
Amoksi
Amoksisillin is an antibiotic of bacterial infections. After the increase in respiratory diseases, the tribe began in October 2022, increasing the demand for antibiotics.
EMA said manufacturers also lacked enough employees to make medicine. This problem has been alleviated in most countries, but some intermittent supply problems persist throughout Europe.
Some suction machine
Asthma, chronic obstructive pulmonary diseases (COPD) and other breathing problems are generally taken for flesh buta malls using a suction or sprayer.
Manufacturers are having difficulty in increasing demand for inhaler, and most EUs are causing intermittent lack of salbutamol. Although alternatives can be used, the shortage is expected to continue at least until mid -2012.
Several types of insulin
Type 1 or type 2 diabetes patients take insulin to control blood sugar. In early 2023, the manufacturing problem for certain types of insulin (Insuman Rapid, Basal and COMB 25) caused a delay in the supply chain.
The pharmaceutical company also decided to stop this type of insulin production, urging the EMA to urge the doctor to convert the patient into another brand.
7 cancer drugs
The EU is not enough to treat a variety of cancer, including Hycamtin, Methotrexate, Fludarabine, Fluorouracil, Cisplatin, Fasturtec and PACLITAXEL.
The unexpected demand for methotrexate injections, which can help to treat inflammation such as rheumatoid arthritis, psoriasis and kroon bottles, due to manufacturing problems has worsened in some European countries.
Lacks have begun to solve some of these drugs, and in the meantime, alternative options for some drugs can be used.
advertisementMosquito -parameters vaccine
IXIAARO is a vaccine of Japanese encephalitis and is associated with dengue fever, yellow fever and West Nile virus and causes brain inflammation. As demand and manufacturing problems increased, the vaccine was insufficient, but the supply level improved.
The EMA predicted that the tribes of Ireland, Italy, Poland, Portugal and Spain were expected to be resolved by the end of January, but the Irish authorities said it will be inventory by the end of April 2025.
Blood disease
PEGINTERFERON ALFA-2A, sold in Pegasys, is used to treat chronic hepatitis B and C and other blood diseases.
Unexpectedly, the higher the demand for pharmaceuticals, the less EMA should be solved in late 2025.
advertisementSchizophrenia
Known as Oranzapin, Zypadhera helps to treat schizophrenia.
Patients who take drugs in the mouth may begin to take the drug through injections, but in some European countries, the need for needles due to manufacturing problems. You can now use limited quantities in the same place as Belgium.
Heart attack prevention drug
Integrilin can prevent heart attacks of adults with severe chest pain and people with certain types of heart attacks.
The supply problem with the active ingredient EPTIFIBATIDE urged the pharmaceutical manufacturer to get out of the EU market without making medicine. But you can use alternatives.
advertisementEye problem medicine
Verteporfin, which is sold as Visudyne, is a treatment like people with certain eye problems such as age -related macular degeneration.
Manufacturing has been limited since May 2020, and other treatments are available, but drugs have been insufficient. In the same place as Austria, you can use limited quantity and re -recover by the end of 2025.
